Back

Clinical Care Options, LLC (dba Decera Clinical Education)

  • Diabetes Mellitus, Type 2
  • Glucagon-Like Peptide-1 Receptor Agonists
  • Incretins

Looking Beyond A1C in T2D Care: Incretin-Based Therapy for Cardiometabolic Risk Reduction

Comprehensive type 2 diabetes T2D management must move beyond A1C alone when creating and adjusting treatment plans which can be done by integrating cardiovascularkidneymetabolic risk reduction strategies and incretinbased therapies Through guidelinebased recommendations and an interactive patient case learners will explore the latest evidence on GLP1 and dual GIPGLP1 receptor agonists and best practices for including these therapies in individualized care plans for patients with T2D and relevant comorbidities being seen in the primary care setting

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

IPCE CreditsUp to 0.5 creditsAAPA Category 1 Credit™Up to 0.5 creditsAMA PRA Category 1 Credit™Up to 0.5 creditsNursingUp to 0.5 credits

MOC types

ABIM — Medical KnowledgeUp to 0.5 points

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • On-demand / recorded video
  • includes Case study / clinical scenario
  • Credit · Up to 0.5 credits
  • MOC · Up to 0.5 points
  • Commercial Support
  • Released
    Aug 10, 2026
  • Last day to claim credit
    Aug 10, 2027 10 months left